New data show Novartis' Gilenya® reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients Novartis, 4 Oct 2013 Accessed on 4 Oct 2013 from http://www.novartis.com/newsroom/media-releases/en/2013/1733406.shtml. CommentRecommendBookmarkWatch